DS107 Drug Market
"DS107 Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about DS107 for Atopic Dermatitis (AD) in the seven major markets. A detailed picture of the DS107 for atopic dermatitis in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 –2032 is provided in this report along with a detailed description of the DS107 for atopic dermatitis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the DS107 market forecast analysis for atopic dermatitis in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in atopic dermatitis.
DS107 Drug Summary
DS107 (DGLA, Daleuton) is a novel, immunomodulating, bioactive lipid that targets the immune activation and skin barrier dysfunction of AD by inhibiting the expression of CD40. Inhibition of CD40 in AD patients down regulates T-cell activation and downstream Th2, Th1, Th17, and Th22 cytokine production. The drug has completed Phase II clinical studies for moderate-to-severe AD in adults in both topical cream and oral formulations.
Scope of the DS107 Drug Market Report
The report provides insights into:
• A comprehensive product overview including the DS107 description, mechanism of action, dosage and administration, research and development activities in atopic dermatitis.
• Elaborated details on DS107 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the DS107 research and development activities in atopic dermatitis across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around DS107.
• The report contains forecasted sales of for atopic dermatitis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for atopic dermatitis.
• The report also features the SWOT analysis with analyst views for DS107 in atopic dermatitis.
DS107 Methodology
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
DS107 Analytical Perspective by DelveInsight
• In-depth DS107 Market Assessment
This report provides a detailed market assessment of DS107 for atopic dermatitis in the seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.
• DS107 Clinical Assessment
The report provides the clinical trials information of DS107 for atopic dermatitis covering trial interventions, trial conditions, trial status, start and completion dates.
DS107 Drug Market Report Highlights
• In the coming years, the market scenario for atopic dermatitis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence DS107 dominance.
• Other emerging products for atopic dermatitis are expected to give tough market competition to DS107 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of DS107 in atopic dermatitis.
• Our in-depth analysis of the forecasted sales data of DS107 from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the DS107 in atopic dermatitis.
Key Questions
• What is the product type, route of administration and mechanism of action of DS107?
• What is the clinical trial status of the study related to DS107 in atopic dermatitis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the DS107 development?
• What are the key designations that have been granted to DS107 for atopic dermatitis?
• What is the forecasted market scenario of DS107 for atopic dermatitis?
• What are the forecasted sales of DS107 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to DS107 for atopic dermatitis?
• Which are the late-stage emerging therapies under development for the treatment of atopic dermatitis?
